Publikationen 

(1-102)

  1. Andreas S. Endocrinological derangement in COPD, Eur Respir J 2010: 35: 933; author reply 934.
  2. Calverley P., Miserocchi G., Puente Maestu L., Aliverti A., De Backer W., Andreas S. et al. The changing face of respiratory physiology: 20 years of progress within the ERS: Clinical Physiology and Integrative Biology Assembly contribution to the celebration of 20 years of the ERS, Eur Respir J 2010: 35: 945-948.
  3. Goeckenjan G., Sitter H., Thomas M., Branscheid D., Flentje M., Griesinger F. et al. Prävention, Diagnose, Therapie, and Nachsorge des Lungenkarzinoms. S3 LL, Pneumologie 2010: 64 Suppl 2: e1-164.
  4. Hoeper M. M., Andreas S., Bastian A., Claussen M., Ghofrani H. A., Gorenflo M. et al. Nicht invasive Diagnostik der pulmonalen Hypertonie. ESC/ERS-Leitlinien mit Kommentierung der Kölner Konsensus Konferenz 2010, Dtsch Med Wochenschr 2010: 135 Suppl 3: S115-124.
  5. Jahne A., Cohrs S., Rodenbeck A., Andreas S., Loessl B., Feige B. et al. Nicotine : Influence on sleep and its relevance for psychiatry and psychotherapy., Der Nervenarzt 2010: 81: 844-859.
  6. Raupach T., Bahr F., Herrmann P., Lüthje L., Hasenfuss G., Andreas S. Inspiratory resistive loading does not increase sympathetic tone in COPD, Respir Med 2010: 104: 107-113.
  7. Raupach T., Shahab L., Eimer S., Puls M., Hasenfuss G., Andreas S. Increasing the use of nicotine replacement therapy by a simple intervention: an exploratory trial, Substance use & misuse 2010: 45: 403-413.
  8. Andreas S. Beta blocker in COPD - precedents in heart failure, Brit Med j 2011: 342 rapid response.
  9. Andreas S., Gamarra F., Herth F., Hoffmann H., Nowak D., Riha S. et al. Non Small Cell Lung Cancer - Prävention und Früherkennung Onkologie 2011: 34 Suppl 4: 2-10.
  10. De Backer W., Simonds A. K., Horn V., Andreas S., Bonsignore M., Calverley P. et al. Sleep HERMES: a European training project for respiratory sleep medicine, Eur Respir J 2011: 38: 496-497.
  11. Floras J., Andreas S. Sleep apnoea and malignant ventricular arrhythmias in heart failure, Eur Heart J 2011: 32: 10-12.
  12. Goeckenjan G., Sitter H., Thomas M., Branscheid D., Flentje M., Griesinger F. et al. Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version, Pneumologie 2011: 65: e51-75.
  13. Hoeper M. M., Andreas S., Bastian A., Claussen M., Ghofrani H. A., Gorenflo M. et al. Pulmonary Hypertension Due to Chronic Lung Disease, Pneumologie 2011: 65: 208-218.
  14. Hoeper M. M., Andreas S., Bastian A., Claussen M., Ghofrani H. A., Gorenflo M. et al. Pulmonary hypertension due to chronic lung disease: Updated Recommendations of the Cologne Consensus Conference 2011, International journal of cardiology 2011: 154S1: S45-S53.
  15. Randerath W. J., Verbraecken J., Andreas S., Bettega G., Boudewyns A., Hamans E. et al. Non-CPAP therapies in obstructive sleep apnoea, Eur Respir J 2011: 37: 1000-1028.
  16. Raupach T., Merker J., Hasenfuss G., Andreas S., Pipe A. Knowledge gaps about smoking cessation in hospitalized patients and their doctors, Eur J Cardiovasc Prev Rehabil 2011: 18: 334-341.
  17. Raupach T., Lüthje L., Kögler H., Duwe C., Schweda F., Hasenfuß G. et al. Effects of angiotensin II type 1 receptor blockade on pulmonary and systemic manifestations in an emphysema mouse model, Pulm Pharmac Ther 2011 24: 215-220.
  18. Andreas S., Raupach T., Kögler H., Hasenfuß G. Angiotensin receptor blockade in pulmonary emphysema, J Clin Invest 2012: 122: 229-letter.
  19. Andreas S., Rittmeyer A. Epidemiologie und Bedeutung tabakassoziierter Lungenkrankheiten, Der Pneumologe 2012: 9: 177-184.
  20. Dalhoff K., Abele-Horn M., Andreas S., Bauer T., von Baum H., Deja M. et al. Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. S-3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, Pneumologie 2012: 66: 707-765.
  21. Haarmann H., Raupach T., Kitz J., Hinterthaner M., Andreas S. EBUS-TBNA in a case of mediastinal lymphangioma, Journal of bronchology & interventional pulmonology 2012: 19: 153-155.
  22. Meier M., Andreas S. Mechanisms of cardiovascular co-morbidity in patients with obstructive sleep apnoea syndrome, Pneumologie 2012: 66: 650-657.
  23. Andreas S., Chenot J.-F., Diebold R., Peachey S., Mann K. Effectiveness of varenicline as an aid to smoking cessation in primary care: An observational study Eur Addict Res 2013: 19: 47-54.
  24. Andreas S., Hasenfuss G. Beneficial effects of Angiotensin receptor blockade in chronic obstructive pulmonary disease, Am J Respir Crit Care Med 2013: 187: 328.
  25. Andreas S., Rittmeyer A., Hinterthaner M., Huber R. M. Smoking Cessation in Lung Cancer-Achievable and Effective, Deutsches Arzteblatt international 2013: 110: 719-724.
  26. Rittmeyer A., Gorbunova V., Vikstrom A., Scherpereel A., Kim J. H., Ahn M. J. et al. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089), J Thorac Oncol 2013: 8: 1409-1416.
  27. Schuette W. H., Groschel A., Sebastian M., Andreas S., Muller T., Schneller F. et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer, Clinical lung cancer 2013: 14: 215-223.
  28. Wachter R., Luthje L., Klemmstein D., Luers C., Stahrenberg R., Edelmann F. et al. Impact of obstructive sleep apnoea on diastolic function, Eur Respir J 2013: 41: 376-383.
  29. Andreas S., Batra A., Behr J., Chenot J. F., Gillissen A., Hering T. et al. Tabakentwöhnung bei COPD, Pneumologie 2014: 68: 237-258.
  30. Andreas S., Haarmann H., Klarner S., Hasenfuss G., Raupach T. Increased Sympathetic Nerve Activity in COPD is Associated with Morbidity and Mortality, Lung 2014: 192: 235-241.
  31. Pepin J. L., Cockcroft J. R., Midwinter D., Sharma S., Rubin D. B., Andreas S. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium, Chest 2014: 146: 1521-1530.
  32. Reinhardt C., Andreas S. COPD: Tabakentwöhnung als essenzieller Bestandteil der Therapie, Deu Med Wochschr 2014: 139: 1240.
  33. Behr J., Kreuter M., Hoeper M. M., Wirtz H., Klotsche J., Koschel D. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry, Eur Respir J 2015: 46: 186-196.
  34. Haarmann H., Mohrlang C., Tschiesner U., Rubin D. B., Bornemann T., Ruter K. et al. Inhaled beta-agonist does not modify sympathetic activity in patients with COPD, BMC pulmonary medicine 2015: 15: 46.
  35. Jimenez-Ruiz C. A., Andreas S., Lewis K. E., Tonnesen P., van Schayck C. P., Hajek P. et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit, Eur Respir J 2015: 46: 61-79.
  36. Reinhardt C., Andreas S. Tabakentwohnung - was gibt es Neues?- Anwort auf Leserbrief, Dtsch Med Wochenschr 2015: 140: 528-529.
  37. Reinhardt C., Andreas S. Tabakentwohnung - was gibt es Neues?, Dtsch Med Wochenschr 2015: 140: 188-190.
  38. Rittmeyer A. Quality of Life in Patients with NSCLC Receiving Maintenance Therapy, Cancers (Basel) 2015: 7: 950-962.
  39. Thomas M., Fischer J., Andreas S., Kortsik C., Grah C., Serke M. et al. Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer, Eur Respir J 2015: 46: 219-229.
  40. Andreas S., Janson C., van den Berge M., Lahousse L. Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?, ERJ Open Res 2016 May 26;2(2) pii: 00055-2016 doi: 101183/2312054100055-2016 eCollection 2016 Apr 2016: 2.
  41. Fehrenbacher L., Spira A., Ballinger M., Kowanetz M., Vansteenkiste J., Mazieres J. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet 2016: 387: 1837-1846.
  42. Flentje M., Huber R. M., Engel-Riedel W., Andreas S., Kollmeier J., Staar S. et al. GILT-A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al] 2016: 192: 216-222.
  43. Haarmann H., Folle J., Nguyen X. P., Herrmann P., Heusser K., Hasenfuss G. et al. Sympathetic Activation is Associated with Exercise Limitation in COPD, Copd 2016: 1-6.
  44. Haarmann H., Folle J., Nguyen X. P., Herrmann P., Heusser K., Hasenfuss G. et al. Impact of Non-Invasive Ventilation on Sympathetic Nerve Activity in Chronic Obstructive Pulmonary Disease, Lung 2016.
  45. Haarmann H., Gossler A., Herrmann P., Bonev S., Nguyen X. P., Hasenfuss G. et al. Effects of varenicline on sympatho-vagal balance and cue reactivity during smoking withdrawal: a randomised placebo-controlled trial, Tobacco induced diseases 2016: 14: 26.
  46. Masefield S., Powell P., Jimenez-Ruiz C., Hajek P., Lewis K., Andreas S. et al. Recommendations to improve smoking cessation outcomes from people with lung conditions who smoke, ERJ Open Res 2016 Apr 27;2(2) pii: 00009-2016 doi: 101183/2312054100009-2016 eCollection 2016 Apr 2016: 2.
  47. Muhlig S., Andreas S., Batra A., Petersen K. U., Hoch E., Ruther T. Psychiatrische Komorbiditaten bei tabakbedingten Storungen, Der Nervenarzt 2016: 87: 46-52.
  48. Pujol J. L., De Pas T., Rittmeyer A., Vallieres E., Kubisa B., Levchenko E. et al. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study, J Thorac Oncol 2016: 11: 2208-2217.
  49. Randerath W., Verbraecken J., Andreas S., Arzt M., Bloch K. E., Brack T. et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep, Eur Respir J 2016.
  50. Rover C., Andreas S., Friede T. Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data, Biometrical journal Biometrische Zeitschrift 2016: 58: 170-185.
  51. Glatzer M., Rittmeyer A., Muller J., Opitz I., Papachristofilou A., Psallidas I. et al. Treatment of limited disease small cell lung cancer: the multidisciplinary team, Eur Respir J 2017: 50.
  52. Guetz S., Tufman A., von Pawel J., Rittmeyer A., Borgmeier A., Ferre P. et al. Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial, Onco Targets Ther 2017: 10: 1081-1089.
  53. Haarmann H., Folle J., Nguyen X. P., Herrmann P., Heusser K., Hasenfuss G. et al. Impact of Non-Invasive Ventilation on Sympathetic Nerve Activity in Chronic Obstructive Pulmonary Disease, Lung 2017: 195: 69-75.
  54. Heigener D. F., Hoeffken G., Wuerflein D., Feurer M., Rittmeyer A., Huber R. M. et al. [Chemotherapy in the Elderly with Non-Small Cell Lung Cancer: A Non-Interventional, Prospective, Multicentric Observational Study], Dtsch Med Wochenschr 2017: 142: e21-e27.
  55. Hirsch F. R., Govindan R., Zvirbule Z., Braiteh F., Rittmeyer A., Belda-Iniesta C. et al. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer, Clinical lung cancer 2017: 18: 43-49.
  56. Kreuter M., Swigris J., Pittrow D., Geier S., Klotsche J., Prasse A. et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry, Respir Res 2017: 18: 139.
  57. Magnussen H., Arzt M., Andreas S., Plate T., Ribera A., Seoane B. et al. Aclidinium bromide improves symptoms and sleep quality in COPD: a pilot study, Eur Respir J 2017: 49.
  58. Randerath W., Verbraecken J., Andreas S., Arzt M., Bloch K. E., Brack T. et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep, Eur Respir J 2017: 49.
  59. Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet 2017: 389: 255-265.
  60. Vansteenkiste J., Wauters E., Park K., Rittmeyer A., Sandler A., Spira A. Prospects and progress of atezolizumab in non-small cell lung cancer, Expert Opin Biol Ther 2017: 17: 781-789.
  61. Alter P., Watz H., Kahnert K., Pfeifer M., Randerath W. J., Andreas S. et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling, Respir Med 2018 Apr;137:14-22 doi: 101016/jrmed201802011 Epub 2018 Feb 19 2018: 137: 14-22.
  62. Andreas S. The association of cardiovascular autonomic dysfunction and the prediction of COPD can be explained by neurohumoral activation, Eur Respir J 2018: 51.
  63. Andreas S., Alt-Epping B. Advance care planning in severe COPD: it is time to engage with the future, ERJ Open Res 2018: 4: pii: 00009-02018.
  64. Andreas S., Bothner U., Trampisch M., Haensel M., Buhl R., Alter P. Effect of long-acting beta2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients, Pulmonary pharmacology & therapeutics 2018: 52: 1-6.
  65. Andreas S., Chouaid C., Danson S., Siakpere O., Benjamin L., Ehness R. et al. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS), Lung cancer 2018.
  66. Andreas S., Jany B., Hering T., Rustler C., Grah C., Pfeifer M. OPS „Tabakentwöhnung“ im DRG-System – eine lohnende Perspektive für Patienten und Klinik., Pneumologie 2018 Feb;72(2):103-105 doi: 101055/s-0044-101117 Epub 2018 Feb 20 2018: 72: 103-105.
  67. Andreas S., Reinhardt C. Increased Arterial Stiffness Might Be Caused by Sympathetic Activation, Chest 2018: 153: 569.
  68. Bordoni R., Ciardiello F., von Pawel J., Cortinovis D., Karagiannis T., Ballinger M. et al. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer, Clinical lung cancer 2018: 19: 441-449 e444.
  69. Chouaid C., Danson S., Andreas S., Siakpere O., Benjamin L., Ehness R. et al. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study, Lung cancer 2018: 124: 310-316.
  70. Claret L., Jin J. Y., Ferte C., Winter H., Girish S., Stroh M. et al. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics, Clin Cancer Res 2018: 24: 3292-3298.
  71. Dalhoff K., Abele-Horn M., Andreas S., Deja M., Ewig S., Gastmeier P. et al. [Epidemiology, Diagnosis and Treatment of Adult Patients with Nosocomial Pneumonia - Update 2017 - S3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German Radiological Society and the Society for Virology], Pneumologie 2018 Jan;72(1):15-63 doi: 101055/s-0043-121734 Epub 2018 Jan 16 2018: 72: 15-63.
  72. Fehrenbacher L., von Pawel J., Park K., Rittmeyer A., Gandara D. R., Ponce Aix S. et al. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer, J Thorac Oncol 2018: 13: 1156-1170.
  73. Gandara D. R., Paul S. M., Kowanetz M., Schleifman E., Zou W., Li Y. et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat Med 2018: 24: 1441-1448.
  74. Gandara D. R., von Pawel J., Mazieres J., Sullivan R., Helland A., Han J. Y. et al. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study, J Thorac Oncol 2018: 13: 1906-1918.
  75. Villalobos M., Czapiewski P., Reinmuth N., Fischer J. R., Andreas S., Kortsik C. et al. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer, Medical oncology 2018: 35: 106.
  76. Alter P., Mayerhofer B. A., Kahnert K., Watz H., Waschki B., Andreas S. et al. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort, Int J Chron Obstruct Pulmon Dis 2019: 14: 2163-2172.
  77. Andreas S., Rover C., Heinz J., Straube S., Watz H., Friede T. Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression, Respir Res 2019: 20: 186.
  78. Gadgeel S. M., Lukas R. V., Goldschmidt J., Conkling P., Park K., Cortinovis D. et al. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study, Lung cancer 2019: 128: 105-112.
  79. Haarmann H., Koch J., Bonsch N., Mende M., Werhahn S. M., Luers C. et al. Morbidity and mortality in patients with cardiovascular risk factors and obstructive sleep apnoea: results from the DIAST-CHF cohort, Respir Med 2019: 154: 127-132.
  80. Kreuter M., Swigris J., Pittrow D., Geier S., Klotsche J., Prasse A. et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry, Respir Res 2019: 20: 59.
  81. Peters S., Stahel R., Bubendorf L., Bonomi P., Villegas A., Kowalski D. M. et al. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers, Clin Cancer Res 2019: 25: 64-72.
  82. Radovic M., Kanesvaran R., Rittmeyer A., Fruh M., Minervini F., Glatzer M. et al. Multidisciplinary treatment of lung cancer in older patients: A review, J Geriatr Oncol 2019: 10: 405-410.
  83. Schiwitza A., Schildhaus H. U., Zwerger B., Ruschoff J., Reinhardt C., Leha A. et al. Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer, Immunotherapy 2019: 11: 769-782.
  84. Villalobos M., Czapiewski P., Reinmuth N., Fischer J. R., Andreas S., Kortsik C. et al. Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab, Oncology letters 2019: 17: 4891-4900.
  85. von Pawel J., Bordoni R., Satouchi M., Fehrenbacher L., Cobo M., Han J. Y. et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study, Eur J Cancer 2019: 107: 124-132.
  86. West H., McCleod M., Hussein M., Morabito A., Rittmeyer A., Conter H. J. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol 2019: 20: 924-937.
  87. Wildung M., Esser T. U., Grausam K. B., Wiedwald C., Volceanov-Hahn L., Riedel D. et al. Transcription factor TAp73 and microRNA-449 complement each other to support multiciliogenesis, Cell death and differentiation 2019: 26: 2740-2757.
  88. Andreas S., Bothner U., de la Hoz A., Kloer I., Trampisch M., Alter P. A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD, Int J Chron Obstruct Pulmon Dis 2020: 15: 1955-1965.
  89. Andreas S., Bothner U., de la Hoz A., Kloer I., Trampisch M., Alter P. No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD, Int J Chron Obstruct Pulmon Dis 2020: 15: 1945-1953.
  90. Andreas S., McGarvey L., Bothner U., Trampisch M., de la Hoz A., Flezar M. et al. Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD, Int J Chron Obstruct Pulmon Dis 2020: 15: 1935-1944.
  91. Andreas S., Taube C. Inhaled therapy reduces COPD mortality, ERJ Open Res 2020: 6.
  92. Behr J., Prasse A., Wirtz H., Koschel D., Pittrow D., Held M. et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry, Eur Respir J 2020: 56.
  93. Brueckl W. M., Reck M., Rittmeyer A., Kollmeier J., Wesseler C., Wiest G. H. et al. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV, Clin Med Insights Oncol 2020: 14: 1179554920951358.
  94. Chalabi M., Cardona A., Nagarkar D. R., Dhawahir Scala A., Gandara D. R., Rittmeyer A. et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials, Ann Oncol 2020: 31: 525-531.
  95. Giese D., Blau J., Knuppel W., Neumann-Schiebener A., Gunther A., Reinhardt C. et al. Vertrag zur prolongierten Beatmungsentwohnung der AOK Hessen-Methodik und erste Erfahrungen., Dtsch Med Wochenschr 2020: 145: e108-e115.
  96. Haidl P., Jany B., Geiseler J., Andreas S., Arzt M., Dreher M. et al. [Guideline for Long-Term Oxygen Therapy - S2k-Guideline Published by the German Respiratory Society], Pneumologie 2020: 74: 813-841.
  97. Iseli T., Berghmans T., Glatzer M., Rittmeyer A., Massard G., Durieux V. et al. Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy, ERJ Open Res 2020: 6.
  98. Omlor A. J., Trudzinski F. C., Alqudrah M., Seiler F., Biertz F., Vogelmeier C. F. et al. Time-updated resting heart rate predicts mortality in patients with COPD, Clin Res Cardiol 2020: 109: 776-786.
  99. Overbeck T. R., Cron D. A., Schmitz K., Rittmeyer A., Korber W., Hugo S. et al. Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis, Transl Lung Cancer Res 2020: 9: 603-616.
  100. Griesinger F., Eberhardt W., Nusch A., Reiser M., Zahn M. O., Maintz C. et al. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315), Lung cancer 2021: 152: 174-184.
  101. Mazieres J., Rittmeyer A., Gadgeel S., Hida T., Gandara D. R., Cortinovis D. L. et al. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials, J Thorac Oncol 2021: 16: 140-150.
  102. Pankow W., Andreas S., Rupp A., Pfeifer M. [Smoking Cessation with E-Cigarettes? - Ad Hoc Statement of the German Respiratory Society (DGP)], Pneumologie 2021: 75: 31-32.

 

 

 

 


Stellenangebote